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Abstract
Background: Although surgical resection has been considered the only curative option for colorectal liver
metastases (CLM), thermal ablation has recently been suggested as an alternative curative treatment. A prospective
randomised trial is required to define the efficacy of resection vs ablation for the treatment of colorectal liver
metastases.
Methods: Design and setting: This is a multicentre, open, randomised controlled non-inferiority trial design with
internal pilot and will be performed in tertiary liver centres in UK and The Netherlands.
Participants: Eligible patients will be those with colorectal liver metastases at high surgical risk because of their age,
co-morbidities or tumour burden and who would be suitable for liver resection or thermal ablation.
Intervention: Thermal ablation as per local policy.
Control: Surgical liver resection performed as per centre protocol.
Co-interventions: Further chemotherapy will be offered to patients as per current practice.
Outcomes
Pilot study: Same as main study and in addition patients and clinicians’ acceptability of the trial to assist in
optimisation of recruitment.
Primary outcome: Disease-free survival (DFS) at two years post randomisation.
Secondary outcomes: Overall survival, timing and site of recurrence, additional therapy after treatment failure,
quality of life, complications, length of hospital stay, costs, trial acceptability, DFS measured from end of
intervention.
Follow-up: 24 months from randomisation; five-year follow-up for overall survival.
Sample size: 330 patients to demonstrate non-inferiority of thermal ablation.
Discussion: This trial will determine the effectiveness and cost-effectiveness of thermal ablation vs surgical
resection for high-risk people with colorectal liver metastases, and guide the optimal treatment for these patients.
Trial registration: ISRCTN Registry, ISRCTN52040363. Registered on 9 March 2016.
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Hepatectomy, Ablation techniques
* Correspondence: k.gurusamy@ucl.ac.uk; b.davidson@ucl.ac.uk
1Royal Free Campus, Division of Surgery and Interventional Science,
University College London, 9th Floor, Royal Free Hospital, Rowland Hill Street,
NW3 2PF, London, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gurusamy et al. Trials  (2018) 19:105 
https://doi.org/10.1186/s13063-018-2499-5
Background
Colorectal liver metastases
Bowel cancer (colorectal cancer) is the UK’s second big-
gest cancer killer and the fourth most common cancer.
Over 41,000 people are diagnosed with bowel cancer
each year in the UK and about 34,000 in England alone.
Just under 16,000 colorectal cancer patients die each
year in the UK, equating to one death every 32 min [1,
2]. About 20% of patients have liver metastases at pres-
entation [3] and another 30% subsequently develop liver
metastases [4]. The resection of colorectal liver metasta-
ses (CLM) has provided a good long-term survival for
many patients who would have previously been treated
with palliative therapy alone [5–8]. However, only about
7–20% of people with CLM undergo potentially curative
liver resection because of the age and co-morbidities of
the patient or because of the extent of cancer spread [7].
Increasing the number of patients who can undergo po-
tentially curative therapy for liver metastases alone is a
main NHS goal for improving the outcome for bowel
cancer patients in the UK. Therefore, specialist liver re-
section centres are carrying out more extensive and
complex resections including elderly patients with major
co-morbidity. This more extensive surgery in patients
with co-morbidity is associated with an increased mor-
bidity and mortality (high-risk patients) [9–14].
Thermal ablation
Thermal ablation is an alternative modality for treatment
of CLM and involves destruction of cancer by heat.
Thermal ablation includes established modalities such as
radiofrequency ablation (RFA) or microwave ablation
(MWA).
Radiofrequency ablation
RFA involves localised destruction of the tumour using
heat generated by high-frequency alternating current to
produce coagulative necrosis of the tumour [15]. For the
treatment of CLM, it is generally carried out as a short-
stay procedure under general anaesthesia, although it
can also be performed under local anaesthesia in some
patients [15]. Multiple sessions may be required to treat
all the tumours in some patients. It can be performed
percutaneously under image guidance (usually CT scan)
but can also be performed by open or laparoscopic sur-
gery [15]. Contraindications for RFA include lesions
close to the hepatic hilum or adjacent to the hepatic
duct as injury may lead to delayed stenosis of the duct
and lesions abutting the bowel because of the risk of
perforation [15]. Lesions near large blood vessels are
often difficult to treat because of dissipation of heat by
circulation [15]. According to the Cardiovascular and
Interventional Radiological Society of Europe (CIRSE)
criteria, RFA is recommended for CLM only when there
are ≤ 5 lesions and tumour size does not exceed 3 cm at
its longest axis [16]. The dose delivered for RFA varies
from one patient to another and is guided by the abla-
tion zone diameter. The target is to heat the tissue to 60
°C at which coagulative necrosis occurs but keep the
electrode tip temperature < 100 °C to avoid charring and
vaporisation of tissue [15].
Microwave ablation
MWA involves localised destruction of the tumour using
heat generated by microwave [17–19]. For the treatment
of liver lesions, it is usually carried out as a short-stay
procedure under general anaesthesia as with RFA, al-
though it can also be performed under local anaesthesia
in some patients [17]. As with RFA, multiple sessions
may be required in some patients to treat all the lesions
(index disease). It is usually performed percutaneously
under image guidance (usually ultrasound scan) [17]. It
is more effective than RFA in lesions near large blood
vessels [17–19]. Major technical limitations of MWA in-
clude low power, shaft heating, large diameter probes,
long and relatively thin (1–2 cm) ablation zones, and un-
predictability regarding the size and shape of the zone of
ablation [17].
Effectiveness of ablation methods
These methods are currently used for patients with
CLM not suitable for surgical resection [20] and not for
patients with a possibility of curative liver resection sur-
gery because of high local recurrence rates with thermal
ablation [21]. Multiple studies have highlighted the su-
periority of surgery to ablation for preventing recurrence
within the liver [21, 22]. A recent series from Nishiwada
et al. showed a 13% recurrence after surgery as opposed
to 46% after thermal ablation [21]. Other newer modal-
ities of thermal ablation include laser ablation and high-
intensity focused ultrasound (HIFU) [23, 24]. Thermal
ablation may be associated with a lower chance of cure
than surgery because of the problem with local recur-
rence. To determine the evidence for thermal ablation, a
National Institute for Health Research (NIHR) Health
Technology Assessment (HTA)-funded systematic re-
view of literature was commissioned and subsequently
published in February 2014 [25]. The systematic review
identified one non-randomised comparative study in
which the survival in patients with RFA was similar to
liver resection surgery despite the RFA group having
more co-morbidities or more extensive liver metastases
[26]. An exploratory cost-effectiveness analysis per-
formed by the group based on this non-randomised
study showed that RFA has the potential to be cheaper
and might result in better health-related quality of life.
Another non-randomised study published since this sys-
tematic review has also shown that patients undergoing
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RFA have survival comparable to surgery despite having
more extensive liver metastases [22]. Similarly, an under-
powered randomised controlled trial (RCT) showed no
evidence of difference in survival between MWA and
liver surgery in resectable CLM [27]. However, in an-
other non-randomised study published after the system-
atic review by Loveman et al., people who were eligible
for surgery but preferred RFA had poorer survival than
those undergoing surgery [28].
Comparison of methods of thermal ablation
Non-randomised studies comparing MWA with RFA
suggested that MWA is better than RFA in terms of
technical feasibility and lower disease recurrence in pa-
tients with unresectable CLM [25]. Of the newer forms
of ablative methods, such as HIFU, CyberKnife®, and
cryotherapy, there are no publications comparing
these newer ablation methods with either RFA or
MWA. In reality, different surgeons and radiologists
have their own preferences of method of ablation be-
cause of this uncertainty.
Potential advantages of thermal ablation over surgery
Current evidence suggests that thermal ablation has
lower complication rates and better health-related qual-
ity of life than surgery [25, 29]. Thermal ablation is also
less expensive than liver resection [25], which will result
in cost savings to NHS. Ablation therapy has the poten-
tial to decrease the pain after treatment and time taken
for recovery from cancer therapy which will decrease the
number of work days lost by the patient and relatives.
Potential concerns about thermal ablation compared with
surgery
The major concern about thermal ablation is the high
incidence of local recurrence and extrahepatic recur-
rence [29]. As a result, it would be anticipated that it
will not offer similar cancer-related outcomes as liver
resection surgery [29]. However, in patients who are
at high surgical risk but would currently be consid-
ered for liver resection [30], the short- and long-term
outcomes after surgery are poorer than the normal
surgical cohort [9–14] and hence thermal ablation
may be a valid alternative to surgery for this group.
Uncertainty in treatment of patients with potentially
resectable colorectal liver metastases
The HTA review suggested that there is equipoise re-
garding treatment using ablation or surgery of elderly
patients and those with significant co-morbidities which
pose significant risk from a surgical procedure and that
good quality evidence of both the clinical benefit and
cost-effectiveness of ablation is required [25]. In sum-
mary, liver resection is a modality with higher short-
term mortality and complication rates and poorer qual-
ity of life during the first 3–6 months but with low local
recurrence rates and a high potential for cure: > 25% of
patients are alive five years after liver resection of
CLM [31]; ablation is a less expensive modality with
practically no short-term mortality, lower complica-
tion rates, earlier recovery, and higher short-term
quality of life but with high local recurrence rates
and the crucial uncertainty of whether it could offer
similar long-term cancer-related outcomes as liver re-
section [30]. From a practical aspect, the choice in
the treatment of patients with potentially resectable
CLM lies between these two modalities.
When can one consider ablation to be equivalent to liver
resection in terms of long-term results?
Liver resection for CLM is a major surgical procedure
and carries a postoperative mortality of approximately
3–4% and a complication rate of ~ 40% [31]. Because of
the effects of major surgery and the associated pain, the
patients take about 2–3 months to recover from surgery
and the quality of life is only 0.65 on a scale of 0 to 1 (1
indicating perfect health) even six months after liver re-
section [25]. As the patient group identified for this trial
are those considered high-risk in terms of age, co-
morbidity and the extent of liver resection required, the
mortality, morbidity and length of hospital stay are likely
to be considerably higher than the average and the
health-related quality of life and recovery period signifi-
cantly greater.
In contrast, the ablative methods have fewer complica-
tions (6%) [26] and the quality of life is 0.74 (on a scale
of 0 to 1) by three months [25]. An informal discussion
with patient representatives from Bowel Cancer UK sug-
gested they were willing to trade-off 3–6 months (aver-
age 4 months) of their long-term survival in return for a
less-invasive procedure with significantly lower compli-
cation rates compared to surgery. So, on average, the
long-term results of ablation and surgery can be consid-
ered equivalent if the difference in long-term survival
between the modalities is < 4 months. Clearly, if ablation
results in similar or better survival, ablation is the better
option since it is less invasive and results in better qual-
ity of life in the short-term.
Choice of patient group to be investigated
There has been no adequately powered RCT comparing
ablation vs surgery in patients with CLM. Retrospective
cohort studies highlight the high local recurrence rate
associated with thermal ablation in comparison to liver
resection surgery but a much lower procedure-related
morbidity and mortality [21, 22]. The options include
performing a RCT for low-risk patients (young patients
without co-morbidities with limited extent of cancer
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spread) with CLM, high-risk patients with CLM, or all
patients with CLM who are suitable for undergoing liver
resection. There is good long-term data on the efficacy
of surgical resection. Surgical resection provides low
rates of local recurrence and disease-free survival (DFS)
proportions of ~ 28% [31]. However, there is a high rate
of local recurrence following thermal ablation and a lack
of long-term data on the efficacy of ablation in patients
with CLM. Because of the known rates of local recur-
rence and the lack of long-term data on cancer out-
comes, the majority of clinicians feel that it is
unethical to randomise low-risk patients to ablation
or surgery despite the short-term benefits of lower
complication rates, less pain and lower costs in pa-
tients undergoing ablation.
While some non-randomised studies did not justify
these concerns and demonstrated equivalent survival
between RFA and liver resection despite patients
undergoing RFA having more co-morbidities or more
extensive cancer [22, 26], another non-randomised
study supported these ethical concerns and demon-
strated that RFA had poorer five-year survival com-
pared to surgery, the only difference between the
patient groups in the second study being their prefer-
ence for RFA or surgery [28].
However, with high-risk patients, there is significant
uncertainty as to the benefits of surgery and the majority
of clinicians feel that there is equipoise between these
modalities for this patient group. These patients have
1.5–2 times lower survival than low surgical risk patients
[12–14]. In this research, we will compare the effective-
ness and cost-effectiveness of ablation vs surgery in this
high-risk group of patients. If this research shows
equivalent results of thermal ablation and surgery in this
group, this will provide justification for a subsequent
clinical trial on low-risk patients.
Aim
The aim of this research is to compare the effectiveness
and cost-effectiveness of thermal ablation vs liver resec-
tion surgery in high-risk patients with CLM.
Methods
The trial has been registered in ISRCTN and can be
accessed at http://www.isrctn.com/ISRCTN52040363.
The SPIRIT (Standard Protocol Items: Recommenda-
tions for Interventional Trials) for this research is
available in Additional file 1 [32].
Design
A prospective, multicentre, open, pragmatic parallel
randomised controlled non-inferiority trial design with
internal pilot to investigate the effectiveness and cost-
effectiveness of ablation (RFA or MWA) compared to
liver resection for the treatment of patients with resect-
able CLM who would be considered high-risk for sur-
gery and with a low chance of cure. The internal pilot
will provide information about the feasibility of recruit-
ment with a qualitative sub-study exploring the reasons
why potential participants agree or do not agree to take
part in the trial and methods of communication about
the trial. The standard of surgical resections and thermal
ablation procedures will be monitored during the in-
ternal pilot, along with assessment of data quality for
key fields. Findings from the pilot will inform whether
any changes are required to the trial design.
Setting/context
Participating sites will be tertiary liver, pancreatic and gall-
bladder (HPB) centres. The trial will open in at least 20 re-
search sites throughout the UK and the Netherlands. It is
anticipated that at least four patients per site per year will
be randomised into the trial, allowing the sample size of
330 patients to be recruited over a four-year period. In the
12-month pilot, we would expect at least 45 patients to be
randomised with at least 15 sites open to recruitment to
establish the feasibility of recruitment required for the
main trial.
Eligibility criteria for surgeons and radiologists
All surgeons and radiologists involved in the trial will
have prior experience of performing relevant (resection
or ablation) procedures for a minimum of 20 patients
with liver cancer. The minimum standards to be
achieved during the trial were discussed in the pre-trial
standardisation meetings. Ablation therapy during open
or laparoscopic surgery could be performed by either a
radiologist or surgeon with sufficient experience.
Sample size calculations
A total of 330 patients are required to demonstrate non-
inferiority (non-inferiority margin of four months) of
thermal ablation with respect to resection in terms of
DFS with 80% power at the 2.5% one-sided level of sig-
nificance, allowing for a four-year accrual period, two-
year follow-up, and assuming 14 months DFS in the re-
section arm and allowing for a 5% drop-out rate.
Participants
The trial will recruit 330 high surgical risk patients eli-
gible for liver resection (165 in each arm). High-risk pa-
tients are defined as any patients that meet at least one
of the following criteria: considered high-risk due to age
(e.g. > 75 years); major co-morbidities as judged by the
treating clinician; liver metastases with poor prognosis
or high-risk surgery due to the tumour burden.
Patients will be identified for trial eligibility at the spe-
cialist liver multi-disciplinary treatment (sMDT) meeting.
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Suitability for inclusion into the trial will be assessed
according to the following eligibility criteria.
Inclusion/exclusion criteria
Inclusion criteria
 Age ≥ 18 years
 Able to provide written informed consent
 MDT diagnosis of colorectal liver metastases
considered to be resectable or ablatable with
curative intent
 Resected colorectal primary or plan for primary
resection with curative intent
 Meets one or more of the following criteria:
a. Considered high-risk for surgery due to age
(based on local policy)
b. Major co-morbidities as judged by the treating
clinician. Examples include history of myocardial
infarction, severe chronic airway disease, major
cerebrovascular accidents (CVA), pulmonary em-
bolism (PE)
c. Liver metastases with poor prognosis and high-
risk surgery due to tumour burden
Examples include extensive synchronous disease,
need for two stage resection or ALPPS, small
anticipated remnant liver volume, curable extra-
hepatic disease, downstaged with chemotherapy,
poor response after chemotherapy but still resect-
able or ablatable
 Suitable candidate for either liver resection surgery
or thermal ablation as judged by the MDT
 Able and willing to comply with the terms of the
protocol including health-related quality of life
(HRQoL) questionnaires
Exclusion criteria
 Incurable extra-hepatic metastases
 Not a suitable candidate for liver resection surgery
 Not a suitable candidate for thermal ablation
 Concurrent malignant disease (except basal cell
carcinoma)
 Patients who have undergone previous surgery or
ablation for CLM
 Planned simultaneous resection of primary and liver
metastases
 Pregnancy
All patients will provide written informed consent. Pa-
tients will then be randomised on a 1:1 basis to receive
either thermal ablation or surgical resection. A
computer-generated minimisation programme that in-
corporates a random element will be used to ensure
treatment groups are well-balanced for the following
participant characteristics:
 Research site
 Synchronous/metachronous disease
 Primary cancer in situ (Yes/No)
 High-risk for surgery due to age (Yes/No)
 Major co-morbidity (Yes/No)
 Poor prognosis or high-risk surgery due to tumour
burden (Yes/No)
 Largest lesion size ≤ 5 cm (Yes/No) [13]
 Planned surgical resection
 Open
 Laparoscopic
 Planned ablative treatment
 RFA
 MWA
Blinding will not be performed.
Pre-treatment investigations
Pre-treatment investigations and preparation will be as
per institutional protocol but must include a baseline
staging computed tomography (CT) scan of chest, abdo-
men and pelvis minimum and tumour markers (CEA as
a minimum) within six weeks of the start of treatment.
Definition of index disease
Index disease is defined as the disease distribution of
CLM metastases at the time of the most recent sMDT
review before the treatment commencing.
Intervention: thermal ablation (RFA or MWA)
Definition of the intervention in the ablation arm
For patients in the ablation arm, the intervention is defined
as the collection of ablation sessions conducted as treat-
ment for the index disease (as defined above). Either RFA
or MWA will be carried out according to the local avail-
ability of equipment and expertise. Ablation may also be
performed at laparoscopic or open surgery if the percutan-
eous approach is contraindicated. Minimum standards for
delivery of ablation to be achieved during the trial will be
agreed by all centres in a pre-trial standardisation meeting.
End of the intervention in the ablation arm
End of trial treatment in the ablation arm is defined
as the end of the final ablation session in the collec-
tion of ablation sessions conducted as treatment of
the index disease.
Control: surgery
Definition of the intervention in the surgical resection arm
For patients in the surgical arm, the intervention is de-
fined as the collection of operations conducted as
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treatment for the index disease (as defined above). Liver
resection will be carried out as per centre protocol. The
majority of patients will have undergone resection of the
primary cancer. Patients may be offered open or laparo-
scopic liver resection depending on site and stage of dis-
ease. In selected cases, the liver first approach may be
considered. Procedures for patients with extensive meta-
static disease will include two-stage liver resection, ven-
ous embolisation or the ALPPS procedure (Associated
Liver Partition and Portal vein ligation for Staged hepa-
tectomy). Minimum surgical outcomes to be achieved
during the trial will be agreed by all centres in a pre-trial
standardisation meeting.
End of the intervention in the surgical arm
End of trial treatment in the surgical resection arm is
defined as the end of the final operation in the collection
of operations conducted as treatment of the index disease.
Post-treatment care
Participants will be reviewed in clinic at 3, 6, 12, 18 and
24 months post randomisation. Follow-up imaging in-
vestigations (CT scan chest, abdomen and pelvis mini-
mum) and tumour markers will be performed following
completion of successful treatment of the index disease
until disease recurrence.
Further treatments
Further chemotherapy will be offered to patients as per
current practice. There is currently no evidence from
RCTs that adjuvant chemotherapy after surgical resec-
tion of CLM improves overall survival [33]. However,
adjuvant chemotherapy after surgical resection im-
proves DFS [33] and may be used in many centres.
Treatment of recurrent disease will depend on the site
and extent of disease and will be decided following re-
view at the sMDT review and following discussion of
the treatment options with patients and their family.
Surgery and ablation are potentially curative treatment
options for recurrent CLM [34–36]. If surgery or abla-
tion is not considered feasible, then palliative chemo-
therapy is usually administered. The median survival
for non-resectable recurrent CLM is approximately 15
months [36].
Participant-completed questionnaires
Participant-completed questionnaires measuring quality
of life (EQ-5D, EORTC QLQ-C30, EORTC LMC21) will
be completed in clinic at baseline (following consent
but before randomisation) and at 3, 6, 12, 18 and 24
months post randomisation. Patient-completed ques-
tionnaires measuring health and social care resource
use will be completed at 3, 6, 12, 18 and 24 months
post randomisation.
Longer-term follow-up
Five-year survival data will be obtained from the Office
of National Statistics (ONS).
CT scan central review
All CT scans performed to assess the outcome of the ab-
lation intervention (e.g. baseline scans and scans typic-
ally carried out around 4–6 weeks after the last ablative
session of treatment) will be centrally reviewed for par-
ticipants in the thermal ablation arm during the pilot
phase. The central review will facilitate quality assurance
of local interpretation of the CT scan findings, e.g. the
completeness/‘success’ of the treatment, the need for
further sessions, etc. To ensure quality assurance follow-
ing the pilot study, review of thermal ablation will be
carried out by the trial interventional radiologists in a
further 20% of the patients chosen at random.
To ensure quality assurance of the reporting of recur-
rence, which feeds into the primary endpoint, a subset
of CT scans performed during the follow up period (e.g.
baseline scans and scans at around 3, 6, 12, 18 and 24
months post randomisation) will be chosen at random
for central review. The selection process will be strati-
fied by centre and outcome (recurrence/no recurrence)
so that the accuracy of reporting of both ‘recurrence’
and ‘no recurrence’ can be assessed across all partici-
pating centres.
Trial organisation
The LAVA trial is funded by the NIHR HTA Programme
(grant reference 13/153/04). The trial is sponsored by
University College London (UCL). The Clinical Trials
Research Unit (CTRU) at the University of Leeds are re-
sponsible for the coordination of the trial. Trial supervi-
sion will be established according to the principles of
Good Clinical Practice (GCP) and in line with the NHS
Research Governance Framework (RGF). This includes
the establishment of a core Project Team, Trial Manage-
ment Group (TMG), an independent Trial Steering
Committee (TSC) and DMEC.
Ethical considerations
The trial will be performed in accordance with the
recommendations guiding physicians in biomedical re-
search involving human subjects adopted by the 18th
World Medical Assembly, Helsinki, Finland, 1964,
amended at the 64th World Medical Association Gen-
eral Assembly, Fortaleza, Brazil, October 2013. In-
formed written consent will be obtained from the
participants before randomisation into the trial. The
right of a patient to refuse participation without giv-
ing reasons must be respected. The participant must
remain free to withdraw at any time from the trial
without giving reasons and without prejudicing his/
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her further treatment. The trial has obtained ethical
approval in the UK and in the Netherlands.
Endpoints
Primary endpoint
DFS at two years post randomisation.
DFS is defined as the time from randomisation to the
first event, which is defined as any of the following:
 Local, regional or extra hepatic/systemic recurrence
of disease
 Death (any cause)
The time-to-event for patients whose treatment fails
will be set equal to 0. If, according to post-
intervention assessment, the index disease is deemed
to have not been successfully removed/eradicated,
then the treatment will be classed as having ‘failed’.
Local recurrence is defined as the detection of disease
at the treatment site after successful trial intervention.
Regional recurrence is defined as detection of disease
in the liver—not related to the treatment site—after
successful trial intervention.
Extra-hepatic/systemic recurrence is defined as detec-
tion of new disease at any site other than the liver after
successful trial intervention. ‘New disease’ refers to any
extra-hepatic/systemic disease which was not already de-
tected before commencement of trial treatment. The
date of recurrence is defined as the date of the relevant
assessment which detected the recurrence.
Secondary outcomes
1. Overall survival, defined as time from randomisation
to death (any cause), evaluated at two and five years
2. Local, regional and extra-hepatic/systemic recur-
rence of disease at two years post randomisation (as
defined above)
3. DFS (measured from end of intervention) at two
years post randomisation (as defined above)
4. Use of subsequent therapies within two years post
randomisation after treatment failure, for example,
use of additional radiofrequency ablation or surgery
for recurrence in either arm
5. Health-related quality of life (EQ-5D, EORTC QLQ-
C30, EORTC LMC21) [37–39] at baseline, and 3, 6,
12, 18 and 24 months post randomisation
6. Complications during treatment
7. Post-treatment complications using Clavien-Dindo
classification system [40, 41]
8. Length of intensive therapy unit (ITU) and inpatient
stay (length of hospital related to treatment or
treatment-related complications) at 30 days and 3
months after completion of treatment
Outcomes related to health economics and qualitative
research are reported under the health economics sec-
tion and qualitative research.
Trial schema
The trial schema is shown in Fig. 1.
Data analysis
Statistical analysis
Analysis and reporting will be in line with CONSORT
guidelines. Analyses will be carried out on both an
intention-to-treat (ITT) basis and per-protocol (PP)
basis. Non-inferiority hypotheses will be tested at the
one-sided 2.5% level of significance. Superiority hypoth-
eses will be tested at the two-sided 5% level of signifi-
cance. 95% confidence intervals for parameter estimates
will also be reported.
The primary analysis will assess the difference in DFS.
The non-inferiority hypothesis will be tested using an
appropriate survival model to incorporate random ef-
fects with respect to research site and including adjust-
ment for the stratification factors. The specific survival
model that is most ‘appropriate’ cannot be determined a
priori; for example, the Cox proportional hazards model
will be considered but will not be used if the propor-
tional hazards assumption is violated. Patients for whom
an event is not reported during their trial follow-up will
be censored at the last date that they were known to not
have had an event.
Differences in rates such as complication rates and re-
currence rates will be analysed using multi-level logistic
regression incorporating random effects with respect to
research site and will include adjustment for the stratifi-
cation factors.
Subgroup analysis based on the type of surgery (open
or laparoscopic liver resection) and type of ablation
(RFA or MWA) will be performed. If there are truly sub-
stantial differences in efficacy between types of treat-
ment within an arm, then these subgroup analyses, while
likely having limited precision, will give an unbiased in-
dication of the magnitude and direction of the differ-
ences. This will allow us to explore how the treatment
effect partitions into these more precise components,
which will allow us to assess the validity of assumption
that there is no substantial difference in efficacy between
open and laparoscopic surgery, and there is no substan-
tial difference between RFA and MWA. This will also
allow us to perform sensitivity analyses using imputation
methods to assess the impact of changing the proportion
of each type of treatment performed within arm on the
primary treatment effect estimate. This will facilitate the
generalisability of our inferences to wider practice and
to potential changes in the uptake of each type of treat-
ment over time.
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Continuous measures such as length of ITU and hos-
pital stay will be analysed using multi-level normal-
errors regression incorporating random effects with
respect to research site and including adjustment for the
stratification factors. In the case of deviation from the
Normality assumptions, the appropriately transformed
variable will be analysed.
Health economic analysis
We will undertake a detailed health economic analysis of
the cost and cost-effectiveness of ablation vs liver resec-
tion for the treatment of high-risk patients with resect-
able CLM. The analysis can be used to evaluate whether
ablation is good value for money in this patient group.
Our analysis will conform to accepted economic
evaluation methods [42]. The RCT is powered to show
that ablation is non-inferior to surgical resection. There
is clear evidence that cost-minimisation analyses in non-
inferiority studies are inappropriate [43, 44]; therefore,
we will undertake an incremental cost-effectiveness ana-
lysis. We will estimate cost-effectiveness during the
‘within-trial’ period (two years/within-trial analysis) and
also over the expected lifetime of the patient (lifetime/
long-run analysis). The within-trial analysis will be based
on resource use, health-related quality of life and sur-
vival data collected in the trial; the long-run analysis will
be based on a decision-analytical model constructed
using trial data supplemented with data from published
sources. In the within-trial analysis, quality-adjusted life-
years (QALYs) will be calculated for each patient based
Fig. 1 Trial schema. The figure shows the pathway that participants who are potentially eligible for the trial follow
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on the survival data and health-related quality of life
data collected during the trial. The latter will be based
on the EQ-5D-5 L (www.euroqol.org), which will be col-
lected at baseline and at 3, 6, 12, 18 and 24 months post
randomisation. Patient-specific utility profiles will be
constructed assuming a straight-line relation between
each of the patient’s EQ-5D scores at each follow-up
point. The QALYs experienced by each patient from
baseline to two years will be calculated as the area
underneath this profile. The within-trial cost analysis
will be based on volume of resource use data collected
for each patient during the trial. Costs will be measured
from the NHS and personal social services (PSS) per-
spective. Cost components included in the analysis will
consist of the detailed cost of the ablation procedures
(including annuitised capital costs plus consumables),
laparoscopic and open surgical resection procedures, the
costs of treating the complications of these procedures,
CT scans and other imaging tests, MDT meetings, costs
of chemotherapy, contacts for receipt of chemotherapy,
contacts and medications for treating the side effects of
chemotherapy, plus other resource use associated with
the cancer and its sequelae (e.g. outpatient attendances,
hospital readmissions, palliative care, primary care con-
tacts, prescribed medications, use of social services in-
cluding hospice care). The volume of resource use for
each cost component will be measured directly in the
trial from patient records and using patient diaries;
unit costs will be taken from standard published
sources. Patient level resource use data will be multi-
plied by the unit costs and summed across all cost
components to calculate total costs per patient over
the two-year period.
Multiple imputation by chained equations will be used
to deal with missing EQ-5D and resource use values.
Subsequent analyses of imputed data will include vari-
ance correction factors to account for additional vari-
ability introduced into parameter values due to the
imputation process.
Cost-effectiveness will be calculated as the mean cost
difference between ablation and surgical resection di-
vided by the mean difference in outcomes (DFS/QALYs)
to give the incremental cost-effectiveness ratio (ICER).
Non-parametric methods for calculating confidence in-
tervals around the ICER based on bootstrapped esti-
mates of the mean cost and QALY differences will be
used [45]. The bootstrap replications will also be used to
construct a cost-effectiveness acceptability curve, which
will show the probability that use of ablative therapy is
cost-effective at two years for different values of the
NHS’ willingness to pay for an additional QALY, and a
cost-effectiveness confidence ellipse. We will also subject
the results to extensive deterministic (one-, two-way,
multi-way, threshold) sensitivity analysis.
In the lifetime model, cost-effectiveness will be calcu-
lated in terms of the incremental cost per QALY gained.
We will undertake a review of the Cost-Effectiveness
Analysis (CEA) Registry (https://healtheconomics.tuft
smedicalcenter.org/cear4/home.aspx) and the NHS Eco-
nomic Evaluation Database (NHS-EED, www.crd.yor
k.ac.uk/) to identify previous economic models that
might be adapted. We will then develop a new cost-
effectiveness model that will be populated based on
available evidence, including the data collected during
the trial. Following decisions about model structure, a
list of parameter estimates required for the model will
be developed. The specific details of the data to be
used to populate the model will be determined fol-
lowing the development of the structure and the sys-
tematic searches of the literature to identify existing
models. We will undertake deterministic and probabilistic
sensitivity analysis, the latter assuming appropriate distri-
butions and parameter values [46]. As part of this, we will
construct cost-effectiveness acceptability curves and cost-
effectiveness confidence ellipses.
We will use the numerator of the ICER described
above to calculate the budget impact of using ablation
compared with surgical resection, multiplying the in-
cremental cost (positive or negative) by the estimated
eligible population size. We will also undertake a
value-of-information study [46] to measure the max-
imum amount to money the NHS should be willing
to pay for additional research to reduce uncertainty
regarding the use of ablation vs surgical resection in
this patient group.
Qualitative sub-study
Recruitment to RCTs with very different treatment
arms can be difficult and recruitment to surgical trials
is particularly challenging [47]. Qualitative research
can identify aspects of the trial design that hinder re-
cruitment and identifying possible solutions [48, 49].
Studies show patient-related (difficulties of informed
consent, understanding randomisation and preference
for certain treatments) and clinician-related factors
(concern about impact on the doctor–patient relation-
ship, clinical equipoise, how trial is presented to pa-
tient) affect recruitment [48–51]. The current trial
compares thermal ablation and surgery for liver me-
tastases, so it is essential to understand and address
barriers to recruitment in order to demonstrate our
ability to undertake the main trial.
Aims
To qualitatively explore patient and clinician acceptabil-
ity of the trial and recruitment processes to assist in
optimisation of recruitment and follow-up strategies
employed for the remainder of the trial.
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Objectives
1. To qualitatively explore patients and clinicians’
acceptability of the trial to assist in optimisation of
recruitment strategies employed for the definitive
trial
2. Explore reasons for participation and non-
participation of eligible patients
3. Understand patients’ experience of the
randomisation process on decision-making
4. Understand why people refuse to participate or do
not take up allocated treatment
5. Patient understanding of trial materials, i.e. do
patients understand what will happen if they take
part and do they understand what they are being
randomised to
6. Acceptability of study procedures
7. Acceptability of randomisation
8. Explore clinical equipoise in the liver surgery
community
9. Understand how information is presented to
recruiters. In particular, explore the content and
style of delivery and feed this back promptly to
recruiters to improve practice
Method
Design: semi-structured interviews A purposive sam-
ple of up to 20 patients will be recruited over nine
months from across the pilot study sites, to include the
three outcomes of consent: (1) participant consented
and accepted treatment allocation; (2) participant con-
sented to randomisation but refused the allocated treat-
ment; (3) participant refused participation in the trial.
In-depth, semi-structured interviews will explore patient
perspectives of treatment, their understanding of the
two treatments, reasons for taking part or refusing the
trial and the acceptability of randomisation between the
procedures.
A purposive sample of approximately 15 healthcare
professionals (local principal investigators, recruiters)
from across the pilot study sites will be interviewed. Par-
ticipants will be selected on the basis of their ability to
shed light on the recruitment process (initial discussion,
recruiter interview). Interviews will explore their views
about the trial, clinical equipoise and their understand-
ing of the recruitment challenges.
Patient and staff interviews will be informed by a topic
guide developed in conjunction with PPI representatives
and informed by the literature. All interviews will be
audio-recorded with permission.
Participant information sessions (recruiter encounters)
will be audio-recorded (with permission) to examine
how information is presented by recruiters and received
and understood by patients, to identify issues potentially
affecting trial recruitment. Information gleaned from the
interviews and listening to the participant information
sessions will inform the development of training mate-
rials for the main trial.
Data analysis All interviews will be professionally tran-
scribed verbatim and managed usingNVivo [52]. The
data will be analysed using thematic analysis [53, 54]
and coded independently by two researchers for emer-
ging themes who will then compare codes and themes
and resolve any disagreements by consensus. The ana-
lysis will be further refined by using constant compari-
son and contrastive approach, and looking for negative
cases. A subset of up to 60 patient recruitment encoun-
ters (audio recordings of recruitment encounters) will be
analysed using content analysis to identify potentially
directive uses of language and good practice.
Information gained will be utilised to optimise patient
information provided relating to the study (recruitment
interview and PIS) and to advise clinical staff about how
to describe the study, which will enable recruitment to
be maximised in the main trial. Our own STAR trial [50]
has confirmed the value of such approaches in improv-
ing recruitment. Emerging issues related to trial design
and conduct that may be responsible for poor recruit-
ment will be discussed with the trial team and a plan to
improve recruitment during the pilot trial will be intro-
duced if necessary. This may include reconsideration of
eligibility criteria, redesign of study information, advice
about presenting the study, discussions about equipoise
or evidence, which may be addressed by changes to
study information, protocol or training for recruiters.
Discussion
With the development of new technologies, new
methods for cancer treatment are being introduced into
the healthcare market and need to be evaluated in terms
of both efficacy and cost-effectiveness in comparison to
competing therapies. Unless this is performed, newer,
more cost-effective therapies will not be introduced into
the NHS or costly treatments which are ineffective may
be adopted. This problem applies at the present time
with the recent introduction of thermal ablation tech-
niques as an alternative to surgery for the treatment of
patients with CLM. If effective, they should be more
widely implemented in the NHS and the technology re-
fined. If they are ineffective, support for more extensive
surgery is required and the technology should be aban-
doned. It is important that any evaluation of effective-
ness and cost-effectiveness between competing therapies
should be based on RCTs, which ensure that similar
types of people receive the two therapies. In addition,
the inclusion criteria and exclusion criteria should be
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such that it should be possible to perform both therapies
in an adequate way in order to maintain equipoise and
to avoid a therapy being considered superior to another
because of the selection of participants to be included in
the trial. In the LAVA trial, we will include only partici-
pants who are eligible for ablation and surgery. Although
we have left it for the local specialist MDT to make the
decision as to whether the potential participant is eli-
gible for both ablation and surgery, we anticipate that
the participants included meet the CIRSE criteria for
RFA for CLM, i.e. ≤ 5 lesions and tumour size does not
exceed 3 cm at its longest axis [16].
Controversies in cost-effectiveness are frequently ad-
dressed through an NIHR-funded HTA. A recent report
on clinical effectiveness and cost-effectiveness of ablative
therapies in the management of liver metastases sug-
gested that a trial investigating the effectiveness and
cost-effectiveness of ablation vs surgery in patients with
resectable CLM is necessary [25]. The long-term results
of ablation and surgery can be considered equivalent
only if the difference in long-term survival between the
modalities is < 4 months due to the recovery period re-
quired following major liver surgery. However, the true
difference in cancer survival between ablation and sur-
gery in patients with CLM is not known.
‘NHS England Strategic and Operational Planning 2014
to 2019’ states the following ‘The healthcare system is fa-
cing the challenge of significant and enduring financial
pressures. People’s need for services will continue to grow
faster than funding, meaning that we have to innovate and
transform the way we deliver high quality services, within
the resources available, to ensure that patients, and their
needs, are always put first.’ Clearly, it is important to maxi-
mise the health of people using the resources available.
This research will achieve this purpose of maximising
the health of people using the resources available. The re-
sults of this research can be adopted immediately in the
UK because of widespread availability of expertise in both
thermal ablation techniques and liver resection surgery,
resulting in maximisation of the health benefits using the
resources available in a short period of time for high-risk
patients with potentially resectable CLM. This research
may also have indirect benefit for low surgical risk patients
with CLM in the long term. The results of the current re-
search will either justify the concerns of clinicians who
consider that thermal ablation is inferior to surgery for the
treatment of patients with CLM (in which case, no RCT
comparing ablation and surgery will be conducted in low
surgical risk patients as it is extremely unlikely that abla-
tion is equivalent or better than surgery in low surgical
risk patients if it offers worse results than surgery in high
surgical risk patients) or it may reassure clinicians that ab-
lation is an effective therapy in which case, a subsequent
RCT may be conducted in low surgical risk patients.
Additional file
Additional file 1: SPIRIT checklist. The completed SPIRIT (Standard
Protocol Items: Recommendations for Interventional Trials) checklist for
this protocol indicating the section in which the issue was covered is
indicated in the table. (DOC 128 kb)
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